Experienced in Lung Nodules

Dr. Kerry P. Pulver

Saint Alphonsus Regional Medical Center Inc
Meridian, ID
Experienced
in Lung Nodules
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
44 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Kerry Pulver is a Hematologist Oncology specialist and an Oncologist in Meridian, Idaho. Dr. Pulver has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Urothelial Cancer, Endometrial Cancer, Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome. Dr. Pulver is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Louisiana State University School Of Medicine In New Orleans, 1981
Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in ID
Hospital Affiliations
Saint Alphonsus Regional Medical Center
Saint Alphonsus Medical Center - Nampa
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  PacificSource

Locations

SAINT ALPHONSUS REGIONAL MEDICAL CENTER INC
3025 W Cherry Ln, Meridian, ID 83642
208-367-2121
Other Locations
SAINT ALPHONSUS REGIONAL MEDICAL CENTER INC
1055 N Curtis Rd, Boise, ID 83706
208-367-2121

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2024
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Enrollment Status: Terminated
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Expertise in
64
conditions
Dr. Bobby Chawla
Hematology Oncology | Hematology | Oncology
Expertise in
64
conditions
Dr. Bobby Chawla
Hematology Oncology | Hematology | Oncology

Saint Alphonsus Regional Medical Center Inc

4400 E Flamingo Ave, 
Nampa, ID 
 (4.6 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bobby Chawla is a Hematologist Oncology specialist and a Hematologist in Nampa, Idaho. Dr. Chawla and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor. Dr. Chawla is currently accepting new patients.

Expertise in
41
conditions
Dr. Mary K. Crow
Hematology Oncology | Hematology | Oncology
Expertise in
41
conditions
Dr. Mary K. Crow
Hematology Oncology | Hematology | Oncology

Saint Alphonsus Regional Medical Center Inc

3025 W Cherry Ln, 
Meridian, ID 
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mary Crow is a Hematologist Oncology specialist and a Hematologist in Meridian, Idaho. Dr. Crow and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Pleuropulmonary Blastoma. Dr. Crow is currently accepting new patients.

Expertise in
63
conditions
Dr. Clinton R. Morgan
Hematology Oncology | Hematology | Oncology
Expertise in
63
conditions
Dr. Clinton R. Morgan
Hematology Oncology | Hematology | Oncology

St Lukes Clinic-Treasure Valley LLC

608 W Hays St, 
Boise, ID 
 (11.7 mi)
208-381-5970
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Clinton Morgan is a Hematologist Oncology specialist and a Hematologist in Boise, Idaho. Dr. Morgan and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Morgan is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile